While ACEIs, ARBs, SGLT2 inhibitors, and dual endothelin/angiotensin receptor antagonists remain foundational therapies, particularly in patients with CKD, emerging agents are increasingly designed to address the underlying immunopathogenesis of IgAN. Here, SLC5A2 is linked to chronic kidney disease.